<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01561209</url>
  </required_header>
  <id_info>
    <org_study_id>AMIT-CNP</org_study_id>
    <nct_id>NCT01561209</nct_id>
  </id_info>
  <brief_title>Low Doses Amitriptyline &amp; Chronic Neck Pain</brief_title>
  <official_title>Prospective Randomized &amp; Controlled Study of the Role of Low Doses Amitriptyline in the Management of Chronic Neck Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St Joseph University, Beirut, Lebanon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St Joseph University, Beirut, Lebanon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this prospective randomized and controlled study is to evaluate the efficacy
      and safety of low dose of amitriptyline (5 mg) in the management of chronic neck pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with chronic neck pain, lasting since at least 3 months, are recruited from our pain
      clinic. After verification of inclusion and exclusion criteria, patients consenting to enter
      the study are assigned randomly to one of the following groups: 1-Amitriptyline 5 mg for 2
      months 2- placebo for 2 months. Co-morbidities and other painful conditions are noted, and
      then clinical evaluation of the patient is performed; pain is assessed according to Visual
      Analog Scale, anxiety, depression, insomnia and disability are evaluated by adapted scores
      (Bergen insomnia scale, neck pain disability score, neck pain diary &amp; anxiety and depression
      score). Patients are followed at 2 months and outcome measures are assessed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Visual analog scale (VAS)</measure>
    <time_frame>0 and 2 months after treatment</time_frame>
    <description>Pain assessment on VAS at 2 months compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Bergen insomnia score</measure>
    <time_frame>0, 2 months</time_frame>
    <description>it assesses the sleep quality of the patient at 2 months compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Neck pain disability score</measure>
    <time_frame>0, 2 months</time_frame>
    <description>NECK PAIN DISABILITY INDEX QUESTIONNAIRE at 2 months compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects</measure>
    <time_frame>Up to 12 weeks after treatment</time_frame>
    <description>reporting the side effects by the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of satisfaction</measure>
    <time_frame>2 months after treatment</time_frame>
    <description>Pain subjective percentage of improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>0 and 2 months after treatment</time_frame>
    <description>Assessment of anxiety and depressive symptoms at 2 months compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">212</enrollment>
  <condition>Neck Pain</condition>
  <arm_group>
    <arm_group_label>Amitryptiline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amitryptiline 5 mg before bedtime</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pill</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amitryptiline</intervention_name>
    <description>Amitryptiline 5 mg before bedtime for 2 months</description>
    <arm_group_label>Amitryptiline</arm_group_label>
    <other_name>Tryptizol</other_name>
    <other_name>Laroxyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pill
1 before bedtime</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>No brand name</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic neck pain (since more than 3 months, and more than 15 days/month)

          -  Normal neurologic exam

          -  X-ray = normal or loss of lordosis

        Exclusion Criteria:

          -  Neurologic signs or symptoms

          -  Past history of neck surgery

          -  MRI = abnormal findings except for loss of lordosis

          -  Past cervical trauma

          -  severe depression

          -  drug abuse

          -  pregnancy

          -  Follow-up not possible

          -  cardiac rhythms problems

          -  Glaucoma

          -  Urinary tract obstruction or prostatism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Maarrawi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Joseph University, Beirut, Lebanon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hotel Dieu de france Hospital</name>
      <address>
        <city>Beirut</city>
        <zip>16 6830</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2012</study_first_submitted>
  <study_first_submitted_qc>March 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2012</study_first_posted>
  <last_update_submitted>August 26, 2017</last_update_submitted>
  <last_update_submitted_qc>August 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St Joseph University, Beirut, Lebanon</investigator_affiliation>
    <investigator_full_name>Dr Joseph Maarrawi</investigator_full_name>
    <investigator_title>Assistant Professor : Researcher - Pain Specialist - Neurosurgeon</investigator_title>
  </responsible_party>
  <keyword>amitryptiline</keyword>
  <keyword>Chronic pain</keyword>
  <keyword>Neck pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neck Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amitriptyline</mesh_term>
    <mesh_term>Amitriptyline, perphenazine drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

